Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 2.80B +106.7% |
| Revenue (ttm) | 295.41M +55.9% |
| Net Income | -49.68M |
| EPS | -0.32 |
| Shares Out | 160.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,560,405 |
| Open | 17.15 |
| Previous Close | 17.36 |
| Day's Range | 17.10 - 18.23 |
| 52-Week Range | 9.90 - 20.76 |
| Beta | 2.15 |
| Analysts | Buy |
| Price Target | 20.14 (+14.95%) |
| Earnings Date | May 5, 2026 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima... [Read more]
Financial Performance
In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price target is $20.14, which is an increase of 14.95% from the latest price.
News
Adaptive Biotechnologies Transcript: 46th Annual William Blair Growth Stock Conference
clonoSEQ continues to lead MRD testing with strong clinical and pharma adoption, driving revenue and margin growth. Expansion in blood-based testing, community settings, and EMR integration supports further market penetration. Immune Medicine advances data partnerships, with positive EBITDA and free cash flow targeted by end of 2026.
Adaptive Biotechnologies Slides: 46th Annual William Blair Growth Stock Conference
Adaptive Biotechnologies has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste...
Adaptive Biotechnologies price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $18 from $21 and keeps an Equal Weight rating on the shares. Published first on…
Adaptive Biotechnologies price target lowered to $19 from $21 at JPMorgan
JPMorgan lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $19 from $21 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Adaptive Biotechnologies price target raised to $21 from $19 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $19 and keeps a Buy rating on the shares. The firm said the company delivered another…
Adaptive Biotechnologies Earnings Call Transcript: Q1 2026
Q1 revenue grew 45% year-over-year, led by 53% MRD growth and record clinical volumes. Sequencing gross margin rose to 70%, and full-year MRD guidance was raised to $260M–$270M. Strong adoption, operational efficiency, and expanding pharma partnerships support continued momentum.
Adaptive Biotechnologies Earnings release: Q1 2026
Adaptive Biotechnologies released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Adaptive Biotechnologies Slides: Q1 2026
Adaptive Biotechnologies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Adaptive Biotechnologies Quarterly report: Q1 2026
Adaptive Biotechnologies has published its Q1 2026 quarterly earnings report on May 5, 2026.
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
Adaptive Biotechnologies Proxy statement: Proxy filing
Adaptive Biotechnologies filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Adaptive Biotechnologies Proxy statement: Proxy filing
Adaptive Biotechnologies filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotechnologies Slides: Corporate presentation
Adaptive Biotechnologies has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Adaptive Biotechnologies Transcript: TD Cowen 46th Annual Health Care Conference
Strong volume growth, guideline inclusions, and pricing improvements are driving double-digit expansion, with EMR integration and clinical data supporting further adoption. International expansion is capital-efficient, and the technology remains the gold standard in MRD, with robust financial margins and a promising immune medicine pipeline.
Adaptive Biotechnologies price target raised to $21 from $20 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps a Buy rating on the shares. The firm updated its model following Q4…
Adaptive Biotechnologies price target raised to $22 from $21 at BTIG
BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares after its Q4 results. The company is firing…
Adaptive Biotechnologies price target raised to $21 from $20 at JPMorgan
JPMorgan analyst Sebastian Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps an Overweight rating on the shares. The firm views the company’s…
Adaptive Biotechnologies Earnings Call Transcript: Q4 2025
Achieved 55% revenue growth and 68% lower cash burn in 2025, with MRD profitability and strong clonoSEQ test volume growth. 2026 guidance targets 22% MRD revenue growth, over 30% test volume increase, and positive company-wide adjusted EBITDA and free cash flow by year-end.
Adaptive Biotechnologies Annual report: Q4 2025
Adaptive Biotechnologies has published its Q4 2025 annual report on February 5, 2026.
Adaptive Biotechnologies Earnings release: Q4 2025
Adaptive Biotechnologies released its Q4 2025 earnings on February 5, 2026, summarizing the period's financial results.
Adaptive Biotechnologies Slides: Q4 2025
Adaptive Biotechnologies has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Adaptive Biotechnologies reports Q4 EPS (9c), consensus (18c)
Reports Q4 revenue $71.68M, consensus $60.9M. The MRD business, which contributed 86% of revenue in the fourth quarter and 77% of revenue in the full year, grew 54% and 46%…